BCL2L1 and ovarian cancer: Western blot analysis was used to demonstrate that treatment of human primary ovarian cancer cells with ACFP at different concentrations for 48 h led to dose-dependent changes in Bcl-xl, Bax, Akt, Caspase-3, CDC25C and CyclinB1 protein levels (Fig. 7a and b).